Our jurisdictional scan yielded no information about phamacogenetic tests that are publicly covered at the population level for select conditions across the jurisdictions reviewed. However, in reviewing the literature, we did find one primary study that examined coverage policies for individual pharmacogenetic tests among six U.S. insurance companies, and we detail the findings in Table 1. This study reveals that coverage policies for specific pharmacogenetic tests varied greatly across insurance companies, and that the majority of tests were deemed experimental/investigational and therefore not eligible for coverage.